It is approved by the Food and Drug Administration (FDA) for weight loss and long-term weight management in adults and adolescents 12 years and older with obesity, as well as adults who are overweight and have at least one weight-related health condition, such as high cholesterol or Type 2 diabetes
It's really helpful, and again, this is a mechanism that is common for the entire body, so the brain and the heart and the kidneys and the liver and because of these two sets of actions of GLP-1 that are both common to the entire body, you perhaps can understand why it has such beneficial effects
Pre-existing conditions that amplify burping Certain conditions make semaglutide-related burping significantly worse
In the second case, a 74-year-old white man who had been taking semaglutide for 1 month presented with an eruption on the bilateral flanks and lower abdomen for 3 weeks duration
A recent head-to-head trial of the peptide drugs found that Lillys tirzepatide, which targets both GLP-1 and GIP receptors, produced greater average weight reductions than Novos semaglutide which targets only GLP-1